Eli Lilly is set to pay InnoCare Pharma up to $3.35 billion to discover and develop compounds against upwards of five undisclosed targets.
Feature|Articles|September 25, 2026
Oral L-Glutamine Could Be Pancreatic Cancer's Most Accessible Treatment Advance: Q&A with Dr. Jun Gong, MD
Author(s)Jun Gong, MD
Adding oral L-glutamine to standard chemo nearly tripled median OS in advanced pancreatic cancer — and what comes next.
Advertisement
Advertisement
Jun Gong, MD, associate professor of medicine and medical director of colorectal cancer at Cedars-Sinai, spoke with Pharmaceutical Executive about the results of a Phase I study that researched the impact of adding oral L-glutamine to first-line gemcitabine/nab-paclitaxel in treatment-naïve advanced pancreatic cancer.
Related to this article
Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.
Drug-delivery failures — not flawed science — are the hidden driver of late-stage trial failures.
Inovalon's Jen Lamppa on why AI's ability to extract insights from unstructured clinical data is foundational to making RWD usable in trials.
Novartis has agreed to pay BoomRay up to $900 million for exclusive global rights to an undisclosed preclinical radioligand therapy asset.
Inovalon's Jen Lamppa on why FDA's acceptance of RWD downstream is a call to action for sponsors to start using it upstream in trial design.
AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Advertisement
Advertisement